In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.

The post Post-Marketing Safety Data for Brexanolone (Zulresso) appeared first on MGH Center for Women’s Mental Health.